Personal information

Emails & domains

Verified email domains

Other IDs

Scopus Author ID: 23488650000
SciProfiles: 1487196

Activities

Collapse all

Works (50 of 63)

Items per page:
Page 1 of 2

Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation

British Journal of Haematology
2025-03 | Journal article
DOI: 10.1111/bjh.19976
Contributors: Francesca Perutelli; Elia Boccellato; Maria Chiara Montalbano; Gioacchino Catania; Marina Deodato; Anna Maria Frustaci; Idanna Innocenti; Riccardo Moia; Francesca Maria Quaglia; Giulia Quaresmini et al.
Source: check_circle
Crossref

Triplets: the bright and the dark side of the moon

Blood
2025-03-20 | Journal article
DOI: 10.1182/blood.2024028110
Contributors: Anna Maria Frustaci; Alessandra Tedeschi
Source: check_circle
Crossref

Depth of Response From Fixed‐Duration Treatment Is Associated With Superior Survival in Waldenstrom Macroglobulinemia

American Journal of Hematology
2025-03-10 | Journal article
DOI: 10.1002/ajh.27663
Contributors: Jonas Paludo; Jithma P. Abeykoon; Nirosha D. Perera; Shayna Sarosiek; Joshua Gustine; Andres Ramirez‐Gamero; Marzia Varettoni; Alessandra Tedeschi; Chiara Cavalloni; Anna Maria Frustaci et al.
Source: check_circle
Crossref

Salvage treatment after covalent BTKi failure: An unmet need in clinical practice in Waldenstrom macroglobulinemia

HemaSphere
2025-02 | Journal article
DOI: 10.1002/hem3.70094
Contributors: Anna Maria Frustaci; Arianna Zappaterra; Andrea Galitzia; Andrea Visentin; Michele Merli; Rita Rizzi; Isacco Ferrarini; Simone Ferrero; Vanessa Innao; Claudia Baratè et al.
Source: check_circle
Crossref

Effectiveness and Tolerability of Dual Antiviral Therapy in Immunosuppressed Patients with Protracted SARS-CoV-2 Infection

Infectious Disease Reports
2025-02-26 | Journal article
DOI: 10.3390/idr17020017
Contributors: Giovanna Travi; Francesco Peracchi; Marco Merli; Emanuele Ravano; Anna Frustaci; Marina Deodato; Diana Fanti; Alice Nava; Valeriana Colombo; Nicholas Brian Bana et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Acalabrutinib in High‐Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real‐Life Experience

Hematological Oncology
2025-01 | Journal article
DOI: 10.1002/hon.70033
Contributors: Idanna Innocenti; Annamaria Tomasso; Diana Giannarelli; Lydia Scarfò; Roberta Murru; Andrea Visentin; Anna Maria Frustaci; Francesca Morelli; Candida Vitale; Antonio Mosca et al.
Source: check_circle
Crossref

Mutational Landscape of Bone Marrow CD19 and CD138 Cells in Waldenström Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM MGUS)

Cancer Medicine
2024-12 | Journal article
DOI: 10.1002/cam4.70525
Contributors: Alessandra Trojani; Alessandro Beghini; Luca Emanuele Bossi; Marta Rachele Stefanucci; Cassandra Palumbo; Antonino Greco; Annamaria Frustaci; Barbara Di Camillo; Roberto Cairoli
Source: check_circle
Crossref

Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort

Hematological Oncology
2024-01 | Journal article
DOI: 10.1002/hon.3249
Contributors: Enrica Antonia Martino; Francesca Romana Mauro; Gianluigi Reda; Luca Laurenti; Andrea Visentin; Annamaria Frustaci; Ernesto Vigna; Sara Pepe; Gioacchino Catania; Giacomo Loseto et al.
Source: check_circle
Crossref

Real‐world evidence on venetoclax in chronic lymphocytic leukemia: The Italian experience

Hematological Oncology
2023-10 | Journal article
DOI: 10.1002/hon.3122
Contributors: Luca Laurenti; Lydia Scarfò; Anna Maria Frustaci; Alessandro Sanna; Emilia Iannella; Morena Caira; Paola Finsinger; Silvia Schifano; Benedetta Neri; Stefano Molica et al.
Source: check_circle
Crossref

Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study

Cancers
2023-05-30 | Journal article
DOI: 10.3390/cancers15112993
Contributors: Francesca R. Mauro; Diana Giannarelli; Clementina M. Galluzzo; Andrea Visentin; Anna M. Frustaci; Paolo Sportoletti; Candida Vitale; Gianluigi Reda; Massimo Gentile; Luciano Levato et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Ibrutinib in patients over 80 years old with CLL: a multicenter Italian cohort

Blood Advances
2023-02-28 | Journal article
DOI: 10.1182/bloodadvances.2022007619
Contributors: Gianluigi Reda; Veronica Mattiello; Anna Maria Frustaci; Andrea Visentin; Francesca Romana Mauro; Idanna Innocenti; Massimo Gentile; Diana Giannarelli; Alessandro Noto; Ramona Cassin et al.
Source: check_circle
Crossref

Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities

Cancers
2023-02-27 | Journal article
DOI: 10.3390/cancers15051504
Contributors: Anna Maria Frustaci; Marina Deodato; Giulia Zamprogna; Roberto Cairoli; Marco Montillo; Alessandra Tedeschi
Source: check_circle
Crossref

Ibrutinib dose intensity in high‐risk chronic lymphocytic leukemia

Hematological Oncology
2022-12 | Journal article
DOI: 10.1002/hon.3032
Contributors: Gabriela Forestieri; Lodovico Terzi di Bergamo; Marina Deodato; Anna Maria Frustaci; Riccardo Moia; Clara Deambrogi; Silvia Rasi; Francesco Autore; Michele Merli; Roberta Mattarucchi et al.
Source: check_circle
Crossref

Should Patients with Waldenström Macroglobulinemia Receive a BTK Inhibitor as Frontline Therapy?

Hemato
2022-10-23 | Journal article
DOI: 10.3390/hemato3040046
Contributors: Marina Deodato; Anna Maria Frustaci; Giulia Zamprogna; Giulia Cotilli; Roberto Cairoli; Alessandra Tedeschi
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial

Blood Advances
2022-09-27 | Journal article
DOI: 10.1182/bloodadvances.2022007138
Contributors: Lydia Scarfò; Silvia Ferrari; Anna Maria Frustaci; Monica Tani; Alessia Bari; Eloise Scarano; Maria Colia; Pamela Ranghetti; Piera Angelillo; Paola Ronchi et al.
Source: check_circle
Crossref

SOHO State of the Art Updates and Next Questions: What is Fitness in the Era of Targeted Agents?

Clinical Lymphoma Myeloma and Leukemia
2022-06 | Journal article
DOI: 10.1016/j.clml.2021.11.009
Contributors: Anna Maria Frustaci; Marina Deodato; Giulia Zamprogna; Roberto Cairoli; Marco Montillo; Alessandra Tedeschi
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three‐factor model

American Journal of Hematology
2022-05 | Journal article
DOI: 10.1002/ajh.26502
Contributors: Stefano Molica; Diana Giannarelli; Andrea Visentin; Gianluigi Reda; Paolo Sportoletti; Anna Maria Frustaci; Annalisa Chiarenza; Stefania Ciolli; Candida Vitale; Luca Laurenti et al.
Source: check_circle
Crossref

Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia

Therapeutic Advances in Hematology
2022-01 | Journal article
DOI: 10.1177/20406207221127550
Contributors: Anna Maria Frustaci; Giovanni Del Poeta; Andrea Visentin; Paolo Sportoletti; Alberto Fresa; Candida Vitale; Roberta Murru; Annalisa Chiarenza; Alessandro Sanna; Francesca Romana Mauro et al.
Source: check_circle
Crossref

Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group

Hematological Oncology
2021 | Journal article
DOI: 10.1002/hon.2861
EID:

2-s2.0-85112378393

Part of ISSN: 10991069 02780232
Contributors: Rigolin, G.M.; Cavazzini, F.; Piciocchi, A.; Arena, V.; Visentin, A.; Reda, G.; Zamprogna, G.; Cibien, F.; Vitagliano, O.; Coscia, M. et al.
Source: Self-asserted source
Anna Maria Frustaci via Scopus - Elsevier

Identification of a candidate gene set signature for the risk of progression in igm mgus to smoldering/symptomatic waldenström macroglobulinemia (Wm) by a comparative transcriptome analysis of b cells and plasma cells

Cancers
2021 | Journal article
DOI: 10.3390/cancers13081837
EID:

2-s2.0-85103908671

Part of ISSN: 20726694
Contributors: Trojani, A.; Di Camillo, B.; Bossi, L.E.; Leuzzi, L.; Greco, A.; Tedeschi, A.; Frustaci, A.M.; Deodato, M.; Zamprogna, G.; Beghini, A. et al.
Source: Self-asserted source
Anna Maria Frustaci via Scopus - Elsevier

Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with ibrutinib

Cancers
2021 | Journal article
DOI: 10.3390/cancers13133240
EID:

2-s2.0-85108735421

Part of ISSN: 20726694
Contributors: Mauro, F.R.; Giannarelli, D.; Visentin, A.; Reda, G.; Sportoletti, P.; Frustaci, A.M.; Chiarenza, A.; Ciolli, S.; Vitale, C.; Laurenti, L. et al.
Source: Self-asserted source
Anna Maria Frustaci via Scopus - Elsevier

Intrahospital COVID‐19 infection outbreak management: Keep calm and carry on

Hematological Oncology
2021-08 | Journal article
DOI: 10.1002/hon.2873
Contributors: Anna M. Frustaci; Maria L. Pioltelli; Emanuele Ravano; Federica Di Ruscio; Daniela A. Campisi; Massimo Puoti; Roberto Cairoli
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Duvelisib for the treatment of chronic lymphocytic leukemia

Expert Opinion on Pharmacotherapy
2020 | Journal article
DOI: 10.1080/14656566.2020.1751123
EID:

2-s2.0-85083588102

Part of ISSN: 17447666 14656566
Contributors: Frustaci, A.M.; Tedeschi, A.; Deodato, M.; Zamprogna, G.; Cairoli, R.; Montillo, M.
Source: Self-asserted source
Anna Maria Frustaci via Scopus - Elsevier

Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection

Leukemia
2020 | Journal article
DOI: 10.1038/s41375-019-0687-2
EID:

2-s2.0-85076354532

Part of ISSN: 14765551 08876924
Contributors: Frigeni, M.; Besson, C.; Visco, C.; Fontaine, H.; Goldaniga, M.; Visentini, M.; Pulsoni, A.; Torres, H.A.; Peveling-Oberhag, J.; Rossotti, R. et al.
Source: Self-asserted source
Anna Maria Frustaci via Scopus - Elsevier

Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation

Biology of Blood and Marrow Transplantation
2020 | Journal article
DOI: 10.1016/j.bbmt.2020.06.032
EID:

2-s2.0-85089254360

Part of ISSN: 15236536 10838791
Contributors: Farina, L.; Barretta, F.; Scarfò, L.; Bruno, B.; Patriarca, F.; Frustaci, A.M.; Coscia, M.; Salvetti, C.; Quaresmini, G.; Fanin, R. et al.
Source: Self-asserted source
Anna Maria Frustaci via Scopus - Elsevier

The management of chronic lymphoproliferative disorders at the time of SARS-Covid2 pandemic: weathering the storm

Leukemia and Lymphoma
2020 | Journal article
DOI: 10.1080/10428194.2020.1797011
EID:

2-s2.0-85088484124

Part of ISSN: 10292403 10428194
Contributors: Frustaci, A.M.; Zamprogna, G.; Deodato, M.; Cairoli, R.; Montillo, M.; Tedeschi, A.
Source: Self-asserted source
Anna Maria Frustaci via Scopus - Elsevier

Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies

American Journal of Hematology
2020 | Journal article
DOI: 10.1002/ajh.25961
EID:

2-s2.0-85090445678

Part of ISSN: 10968652 03618609
Contributors: Varettoni, M.; Ferrari, A.; Frustaci, A.M.; Ferretti, V.V.; Rizzi, R.; Motta, M.; Piazza, F.; Merli, M.; Benevolo, G.; Visco, C. et al.
Source: Self-asserted source
Anna Maria Frustaci via Scopus - Elsevier

Health‐related quality of life in Waldenstrom Macroglobulinemia and IgM‐related disorders: A single institution experience

Hematological Oncology
2020-02 | Journal article
DOI: 10.1002/hon.2699
Contributors: Anna Maria Frustaci; Michele Nichelatti; Marina Deodato; Giulia Zamprogna; Periana Minga; Maria Luisa Pioltelli; Roberto Cairoli; Alessandra Tedeschi
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network

American Journal of Hematology
2019 | Journal article
DOI: 10.1002/ajh.25600
EID:

2-s2.0-85072035201

Part of ISSN: 10968652 03618609
Contributors: Varettoni, M.; Boveri, E.; Zibellini, S.; Tedeschi, A.; Candido, C.; Ferretti, V.V.; Rizzo, E.; Doni, E.; Merli, M.; Farina, L. et al.
Source: Self-asserted source
Anna Maria Frustaci via Scopus - Elsevier

Duvelisib: A new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia

Future Oncology
2019 | Journal article
DOI: 10.2217/fon-2018-0881
EID:

2-s2.0-85069504533

Part of ISSN: 17448301 14796694
Contributors: Frustaci, A.M.; Tedeschi, A.; Deodato, M.; Zamprogna, G.; Cairoli, R.; Montillo, M.
Source: Self-asserted source
Anna Maria Frustaci via Scopus - Elsevier

Elevated lactate dehydrogenase has prognostic relevance in treatment-naïve patients affected by chronic lymphocytic leukemia with trisomy 12

Cancers
2019 | Journal article
DOI: 10.3390/cancers11070896
EID:

2-s2.0-85068657961

Part of ISSN: 20726694
Contributors: Autore, F.; Strati, P.; Innocenti, I.; Corrente, F.; Trentin, L.; Cortelezzi, A.; Visco, C.; Coscia, M.; Cuneo, A.; Gozzetti, A. et al.
Source: Self-asserted source
Anna Maria Frustaci via Scopus - Elsevier

Ibrutinib for the treatment of chronic lymphocytic leukemia

Expert Review of Hematology
2019 | Journal article
DOI: 10.1080/17474086.2019.1597703
EID:

2-s2.0-85064490274

Part of ISSN: 17474094 17474086
Contributors: Deodato, M.; Frustaci, A.M.; Zamprogna, G.; Cairoli, R.; Montillo, M.; Tedeschi, A.
Source: Self-asserted source
Anna Maria Frustaci via Scopus - Elsevier

Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience

British Journal of Haematology
2019 | Journal article
DOI: 10.1111/bjh.16123
EID:

2-s2.0-85072628454

Part of ISSN: 13652141 00071048
Contributors: Innocenti, I.; Morelli, F.; Autore, F.; Piciocchi, A.; Frustaci, A.; Mauro, F.R.; Schiattone, L.; Trentin, L.; Del Poeta, G.; Reda, G. et al.
Source: Self-asserted source
Anna Maria Frustaci via Scopus - Elsevier

Waldenström's macroglobulinemia front line treatment

HemaSphere
2019 | Journal article
DOI: 10.1097/HS9.0000000000000222
EID:

2-s2.0-85088222721

Part of ISSN: 25729241
Contributors: Tedeschi, A.; Frustaci, A.M.
Source: Self-asserted source
Anna Maria Frustaci via Scopus - Elsevier

Ibrutinib and its use in the treatment of chronic lymphocytic leukemia

Future Oncology
2018 | Journal article
DOI: 10.2217/fon-2017-0466
EID:

2-s2.0-85045327473

Part of ISSN: 17448301 14796694
Contributors: Frustaci, A.M.; Tedeschi, A.; Deodato, M.; Mazzucchelli, M.; Cairoli, R.; Montillo, M.
Source: Self-asserted source
Anna Maria Frustaci via Scopus - Elsevier

Waldenstrom's macroglobulinemia: An update

Mediterranean Journal of Hematology and Infectious Diseases
2018 | Journal article
DOI: 10.4084/MJHID.2018.004
EID:

2-s2.0-85040524615

Part of ISSN: 20353006
Contributors: Mazzucchelli, M.; Frustaci, A.M.; Deodato, M.; Cairoli, R.; Tedeschi, A.
Source: Self-asserted source
Anna Maria Frustaci via Scopus - Elsevier

Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma

American Journal of Hematology
2017 | Journal article
DOI: 10.1002/ajh.24714
EID:

2-s2.0-85018575095

Part of ISSN: 10968652 03618609
Contributors: Mauro, F.R.; Galieni, P.; Tedeschi, A.; Laurenti, L.; Del Poeta, G.; Reda, G.; Motta, M.; Gozzetti, A.; Murru, R.; Caputo, M.D. et al.
Source: Self-asserted source
Anna Maria Frustaci via Scopus - Elsevier

Is HBV prophylaxis required during CLL treatment with ibrutinib?

Leukemia and Lymphoma
2017 | Journal article
DOI: 10.1080/10428194.2017.1317094
EID:

2-s2.0-85019601300

Part of ISSN: 10292403 10428194
Contributors: Tedeschi, A.; Frustaci, A.M.; Mazzucchelli, M.; Cairoli, R.; Montillo, M.
Source: Self-asserted source
Anna Maria Frustaci via Scopus - Elsevier

Bing Neel Syndrome in a Previously Untreated Patient with Waldenström's Macroglobulinemia: Contribution of MYD88 L265P Mutation on Cerebrospinal Fluid

Clinical Lymphoma, Myeloma and Leukemia
2016 | Journal article
DOI: 10.1016/j.clml.2015.11.004
EID:

2-s2.0-84952056728

Part of ISSN: 21522669 21522650
Contributors: Frustaci, A.M.; Rusconi, C.; Picardi, P.; Veronese, S.; Montillo, M.; Cairoli, R.; Tedeschi, A.
Source: Self-asserted source
Anna Maria Frustaci via Scopus - Elsevier

Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future?

Expert Review of Hematology
2016 | Journal article
DOI: 10.1080/17474086.2016.1191943
EID:

2-s2.0-84977071107

Part of ISSN: 17474094 17474086
Contributors: Frustaci, A.M.; Montillo, M.; Picardi, P.; Mazzucchelli, M.; Cairoli, R.; Tedeschi, A.
Source: Self-asserted source
Anna Maria Frustaci via Scopus - Elsevier

A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients

Haematologica
2015 | Journal article
DOI: 10.3324/haematol.2015.132035
EID:

2-s2.0-84948989490

Part of ISSN: 15928721 03906078
Contributors: Tedeschi, A.; Rossi, D.; Motta, M.; Quaresmini, G.; Rossi, M.; Coscia, M.; Anastasia, A.; Rossini, F.; Cortelezzi, A.; Nador, G. et al.
Source: Self-asserted source
Anna Maria Frustaci via Scopus - Elsevier

Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia

Leukemia and Lymphoma
2015 | Journal article
DOI: 10.3109/10428194.2015.1012714
EID:

2-s2.0-84942548240

Part of ISSN: 10292403 10428194
Contributors: Tedeschi, A.; Picardi, P.; Ferrero, S.; Benevolo, G.; Margiotta Casaluci, G.; Varettoni, M.; Baratè, C.; Motta, M.; Gini, G.; Goldaniga, M.C. et al.
Source: Self-asserted source
Anna Maria Frustaci via Scopus - Elsevier

Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia

Biologics: Targets and Therapy
2015 | Journal article
DOI: 10.2147/BTT.S60503
EID:

2-s2.0-84942306096

Part of ISSN: 11775491 11775475
Contributors: Frustaci, A.M.; Tedeschi, A.; Picardi, P.; Cairoli, R.; Montillo, M.
Source: Self-asserted source
Anna Maria Frustaci via Scopus - Elsevier

Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients

Haematologica
2014 | Journal article
DOI: 10.3324/haematol.2014.106740
EID:

2-s2.0-84907374559

Part of ISSN: 15928721 03906078
Contributors: Montillo, M.; Tedeschi, A.; Gaidano, G.; Coscia, M.; Petrizzi, V.B.; Orlandi, E.; Cascavilla, N.; Ghia, P.; Motta, M.; Gallamini, A. et al.
Source: Self-asserted source
Anna Maria Frustaci via Scopus - Elsevier

Fludarabine, cyclophosphamide, and rituximab in salvage therapy of waldenström's macroglobulinemia

Clinical Lymphoma, Myeloma and Leukemia
2013 | Journal article
DOI: 10.1016/j.clml.2013.02.011
EID:

2-s2.0-84877609890

Part of ISSN: 21522650 21522669
Contributors: Tedeschi, A.; Ricci, F.; Goldaniga, M.C.; Benevolo, G.; Varettoni, M.; Motta, M.; Pioltelli, P.; Gini, G.; Barate', C.; Luraschi, A. et al.
Source: Self-asserted source
Anna Maria Frustaci via Scopus - Elsevier

New category of probable invasive pulmonary aspergillosis in haematological patients

Clinical Microbiology and Infection
2012 | Journal article
DOI: 10.1111/j.1469-0691.2011.03685.x
EID:

2-s2.0-84866165930

Part of ISSN: 14690691 1198743X
Contributors: Girmenia, C.; Guerrisi, P.; Frustaci, A.M.; Fama, A.; Finolezzi, E.; Perrone, S.; Gentile, G.; Collerone, F.; Brocchieri, S.; Guerrisi, V.
Source: Self-asserted source
Anna Maria Frustaci via Scopus - Elsevier

Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: A single-center, real-life experience

Haematologica
2012 | Journal article
DOI: 10.3324/haematol.2011.053058
EID:

2-s2.0-84859476239

Part of ISSN: 03906078 15928721
Contributors: Girmenia, C.; Frustaci, A.M.; Gentile, G.; Minotti, C.; Cartoni, C.; Capria, S.; Trisolini, S.M.; Matturro, A.; Loglisci, G.; Latagliata, R. et al.
Source: Self-asserted source
Anna Maria Frustaci via Scopus - Elsevier

"Real-life" results of front-line treatment with Imatinib in older patients (≥65 years) with newly diagnosed chronic myelogenous leukemia

Leukemia Research
2010 | Journal article
DOI: 10.1016/j.leukres.2010.07.001
EID:

2-s2.0-77957021650

Part of ISSN: 01452126
Contributors: Latagliata, R.; Breccia, M.; Carmosino, I.; Cannella, L.; De Cuia, R.; Diverio, D.; Frustaci, A.; Loglisci, G.; Mancini, M.; Santopietro, M. et al.
Source: Self-asserted source
Anna Maria Frustaci via Scopus - Elsevier

Analysis of prognostic factors in patients with refractory anemia with excess of blasts (RAEB) reclassified according to WHO proposal

Leukemia Research
2009 | Journal article
DOI: 10.1016/j.leukres.2008.06.033
EID:

2-s2.0-58549085387

Part of ISSN: 01452126
Contributors: Breccia, M.; Latagliata, R.; Cannella, L.; Carmosino, I.; De Cuia, R.; Frustaci, A.; Stefanizzi, C.; Santopietro, M.; Alimena, G.
Source: Self-asserted source
Anna Maria Frustaci via Scopus - Elsevier

Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients

Hematological Oncology
2009 | Journal article
DOI: 10.1002/hon.889
EID:

2-s2.0-70349349621

Part of ISSN: 02780232 10991069
Contributors: Breccia, M.; Frustaci, A.M.; Cannella, L.; Stefanizzi, C.; Latagliata, R.; Cartoni, C.; Diverio, D.; Guarini, A.; Nanni, M.; Rago, A. et al.
Source: Self-asserted source
Anna Maria Frustaci via Scopus - Elsevier
Items per page:
Page 1 of 2

Peer review (2 reviews for 2 publications/grants)

Review activity for Advances in therapy. (1)
Review activity for Annals of hematology. (1)
How many people are using ORCID?